This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
All Wales Medicines Strategy Group (AWMSG). Linagliptin (Trajenta®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 0112. 2012
Linagliptin (Trajenta®) is not recommended for use within NHS Wales for the treatment of type 2 diabetes mellitus to improve glycaemic control in adults as:
in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.
in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.
in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control
The evidence presented in the submission was insufficiently robust for AWMSG to recommend its use.
Subject indexing assigned by CRD
Diabetes Mellitus, Type 2s; Dipeptidyl-Peptidase IV Inhibitors; Purines; Quinazolines
Country of organisation
An English language summary is available.
Address for correspondence
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Date abstract record published